Polyether from a biobased Janus molecule as surfactant for carbon nanotubes

A new polyether (PE) was prepared from a biobased Janus molecule, 2-(2,5-dimethyl-1H-pyrrol-1-yl)-1,3- propanediol (serinol pyrrole, SP). SP was synthesized with very high yield (about 96%) and high atom efficiency (about 80%) by reacting a biosourced molecule, such as serinol, with 2,5-hexanedione in the absence of solvent or catalyst. The reaction of SP with 1,6-dibromohexane led to PE oligomers, that were used as surfactants for multiwalled carbon nanotubes (MWCNT), in ecofriendly polar solvents such as acetone and ethyl acetate. The synergic interaction of aromatic rings and oxyalkylene sequences with the carbon allotrope led to dramatic improvement of surfactant efficiency: only 24% of SP based PE was extracted with ethyl acetate from the adduct with MWCNT, versus 98% of a typical pluronic surfactant. Suspensions of MWCNT-PE adducts in ethyl acetate were stable for months. High resolution transmission electron microscopy revealed a film of oligomers tightly adhered to MWCNT surface

Gentling and welfare of lambs

In traditional sheep production systems, lambs are suckled by their mothers and then gradually weaned at 35 days of age. However, the increased size of intensive dairy sheep flocks to obtain greater amounts of ovine milk for cheese making, is promoting the diffusion of artificial rearing programs involving early separation of lambs from their mothers. Maternal deprivation soon after birth can have detrimental effects on lamb immune functions, and lead to altered cortisol secretion and behavioural responses to isolation (Napolitano et al., 1995). Human-animal interactions have been documented to play a role in sustaining the welfare and production of domestic animals (Hemsworth, 2003). In addition, gentled animals are less difficult to be handled and less susceptible to the stress induced by management practices involving human contacts (Lensink et al., 2000). The aim of the present trial was to investigate the effects of gently handling newborn lambs on their behavioural, immune and endocrine responses, and on their growth rate when mothered or artificially reared

Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned.

The COVID-19 pandemic has created unprecedented hurdles to the delivery of care to patients with cancer. Patients with hematologic malignancies appear to have a greater risk of SARS-CoV-2 infection and severe disease due to myelosuppression and lymphopenia. The first challenge, therefore, is how to continue to deliver effective, curative therapy to vulnerable patients and at the same time avoid exposing them, and their health care teams (HCT), to SARS-CoV-2. An additional challenge is the timely completion of the diagnostic and staging studies required to formulate appropriate treatment plans. Deferred procedures and avoidance of multiple trips to the surgical, diagnostic, and laboratory suites require same day consolidation of all procedures. With laboratory medicine absorbed by the need to deploy large scale COVID-testing, the availability of routine molecular tests is affected. Finally, we are increasingly faced with the challenge of making complex treatment decisions in SARS-CoV-2 positive patients with aggressive but potentially curable blood cancers. When to treat, how to treat, when to wait, how long to wait, how to predict and manage toxicities, and how to avoid compromising cure rates remains unknown. We present an outline of the scientific, medical, and operational challenges posed by the COVID-19 pandemic at selected American and European institutions and offer our current view of the key elements of a response. While the peak of the pandemic may be past us, in the absence of a vaccine risks remain, and our alertness and response to future challenges need to be refined and consolidated

Infrared nanospectroscopy of individual extracellular microvesicles

Extracellular vesicles are membrane-delimited structures, involved in several inter-cellular communication processes, both physiological and pathological, since they deliver complex biological cargo. Extracellular vesicles have been identified as possible biomarkers of several pathological diseases; thus, their characterization is fundamental in order to gain a deep understanding of their function and of the related processes. Traditional approaches for the characterization of the molecular content of the vesicles require a large quantity of sample, thereby providing an average molecular profile, while their heterogeneity is typically probed by non-optical microscopies that, however, lack the chemical sensitivity to provide information of the molecular cargo. Here, we perform a study of individual microvesicles, a subclass of extracellular vesicles generated by the outward budding of the plasma membrane, released by two cultures of glial cells under different stimuli, by applying a state-of-the-art infrared nanospectroscopy technique based on the coupling of an atomic force microscope and a pulsed laser, which combines the label-free chemical sensitivity of infrared spectroscopy with the nanometric resolution of atomic force microscopy. By correlating topographic, mechanical and spectroscopic information of individual microvesicles, we identified two main populations in both families of vesicles released by the two cell cultures. Subtle differences in terms of nucleic acid content among the two families of vesicles have been found by performing a fitting procedure of the main nucleic acid vibrational peaks in the 1000–1250 cm-1 frequency range

Epitranscriptomics in normal and malignant hematopoiesis

Epitranscriptomics analyze the biochemical modifications borne by RNA and their downstream influence. From this point of view, epitranscriptomics represent a new layer for the control of genetic information and can affect a variety of molecular processes including the cell cycle and the differentiation. In physiological conditions, hematopoiesis is a tightly regulated process that produces differentiated blood cells starting from hematopoietic stem cells. Alteration of this process can occur at different levels in the pathway that leads from the genetic information to the phenotypic manifestation producing malignant hematopoiesis. This review focuses on the role of epitranscriptomic events that are known to be implicated in normal and malignant hematopoiesis, opening a new pathophysiological and therapeutic scenario. Moreover, an evolutionary vision of this mechanism will be provided

FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches

FMS-like tyrosine kinase 3 (FLT3) is one of the most closely studied genes in blood diseases. Numerous methods have been adopted for analyses, mainly in acute myeloid leukemia (AML) diagnostic work-up. According to international recommendations, the current gold standard approach allows FLT3 canonical mutations to be investigated, providing the main information for risk assessment and treatment choice. However, the technological improvements of the last decade have permitted “black side” gene exploration, revealing numerous hidden aspects of its role in leukemogenesis. The advent of the next-generation sequencing era emphasizes lights and shadows of FLT3 conventional mutational analysis, highlighting the need for a more comprehensive study of the gene. However, more extensive analysis is opening new, unexplored questions whose impact on clinical outcomes is still unknown. The present work is focused on the main topics regarding FLT3 mutational analysis in AML, debating the strengths and weaknesses of the current gold standard approach. The rights and wrongs of NGS introduction in clinical practice will be discussed, showing that a more extensive knowledge of FLT3 mutational status could lead to reconsidering its role in AML management

Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a rare, distinct subtype of T-ALL characterized by genomic instability, a dismal prognosis and refractoriness to standard chemotherapy. Since its first description in 2009, the expanding knowledge of its intricate biology has led to the definition of a stem cell leukemia with a combined lymphoid-myeloid potential: the perfect trick. Several studies in the last decade aimed to better characterize this new disease, but it was recognized as a distinct entity only in 2016. We review current insights into the biology of ETP-ALL and discuss the pathogenesis, genomic features and their impact on the clinical course in the precision medicine era today

Thermo-Induced Fluorochromism in Two AIE Zinc Complexes: A Deep Insight into the Structure-Property Relationship

Solid-state emitters exhibiting mechano-fluorochromic or thermo-fluorochromic responses represent the foundation of smart tools for novel technological applications. Among fluo-rochromic (FC) materials, solid-state emissive coordination complexes offer a variety of fluorescence responses related to the dynamic of noncovalent metal-ligand coordination bonds. Relevant FC behaviour can result from the targeted choice of metal cation and ligands. Herein, we report the synthesis and characterization of two different colour emitters consisting of zinc complexes obtained from N,O bidentate ligands with different electron-withdrawing substituents. The two complexes are blue and orange solid-state fluorophores, respectively, highly responsive to thermal and me-chanical stress. These emitters show a very different photoluminescent (PL) pattern as recorded before and after the annealing treatment. Through X-ray structural analysis combined with thermal analysis, infrared (IR) spectroscopy, PL, and DFT simulation we provide a comprehensive analysis of the structural feature involved in the fluorochromic response. Notably, we were able to correlate the on-off thermo-fluorochromism of the complexes with the structural rearrangement at the zinc coordination core

Distal esophageal involvement in Crohn disease: short treatment with adalimumab

n/